Navigation Links
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Date:2/12/2009

ef="http://www.pharmacyclics.com" target="_new">http://www.pharmacyclics.com.

NOTE: Other than statements of historical fact, the statements made in this press release about future plans for and the timing of initiation of our clinical trials, progress of and reports of results from preclinical and clinical studies, expected effect of our products under development, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchan
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Secures $5.0 Million in Debt Financing
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Pharmacyclics Announces It Received Nasdaq Notification
6. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
7. Savient Announces Appointment of David Gionco as Chief Financial Officer
8. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
9. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
10. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
11. Cord Blood Announces $1 Million Reduction in Long Term Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 29, 2015 , ... The global microfluidics market is expected ... (2015 to 2020). The market is mainly driven by the rising geriatric population, ... However, lack of adequate healthcare and research infrastructure in emerging markets, dearth of ...
(Date:6/29/2015)... 2015  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical ... molecule and cell therapy treatments for central nervous system ... listing on the NASDAQ Capital Market under the symbol ... on the NYSE MKT until the market close on ... is expected to commence on July 13, 2015. ...
(Date:6/29/2015)...   For the seventh year running, Across Health conducted ... digital maturity called the Multichannel Maturometer . The ... maturing fast enough. While it,s true that technology is ... and customers are increasingly "digital natives", pharma still lags ... ...
(Date:6/26/2015)... , June 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced that all nominees listed in the management ... at its 2015 Annual Meeting of Shareholders, held ... by ballot, the following 5 nominees proposed by ... to serve until the Company,s next Annual Meeting ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... Group, Inc.,released its third annual TreatmentTrends(TM): The Use ... the management of,Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), ... responses to an online survey,completed by 100 US ... study, the majority of Rheumatologists reported an,increase in ...
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... scheduled to participate in the upcoming UBS Global Life,Sciences ... York City., D. Ashley Lee, executive vice president, ... will present Wednesday,September 24 at 2:30 p.m., Eastern Time., ...
... Conn., Sept. 17 MannKind Corporation,(Nasdaq: MNKD ) ... States,Food and Drug Administration to use AFRESA as the ... uh-FRESS-uh) was unveiled today by Alfred Mann,Chairman and Chief ... Danbury, Conn., location that marked the completion and,dedication of ...
Cached Biology Technology:Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis? 2CryoLife to Present at UBS Global Life Sciences Conference 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 3
(Date:6/11/2015)... , June 11, 2015 Daon, a ... today that its IdentityX Mobile Authentication Platform v4.0 ... Online) Alliance is an industry consortium launched in ... for simpler, stronger authentication.  In order to receive ... a rigorous series of tests that measure compliance ...
(Date:6/9/2015)... Minn. , June 9, 2015   MedNet ... supports the entire spectrum of clinical research, will be ... eClinical technology platform at the 2015 Drug Information Association ... on June 15-17.  These presentations will include previews ... rolled out in the upcoming iMedNet 2015 ...
(Date:6/8/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of cell-free ... Cancer Monitoring SM platform will be presented at the ... San Diego, CA on June 11-12 , ... Genomics and Cancer Therapy in Salt Lake ... "We continue to advance our clinical programs and present data ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... forests, a Michigan State University (MSU) sustainability scholar proposes a ... fall in China, can you hear it elsewhere in the ... Pacific Policy Studies , MSU,s University Distinguished Professor Jianguo "Jack" ... and expand its forests even as its cities and population ...
... presence of male sperm and seminal fluid causes female worms to ... week in the journal Science . The demise of the ... the mating pool for other males. The researchers found ... to dehydrate, prematurely age and die. "Their lifespans are ...
Cached Biology News:ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3Telecoupling science shows China's forest sustainability packs global impact 2Mating is the kiss of death for certain female worms 2Mating is the kiss of death for certain female worms 3
... Sigma-Genosys offers custom peptide synthesis with a wide ... best fit your research needs. Purity: ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, ...
... liquid handling system from Molecular Devices provides ... one instrument. The system handles a variety ... washing96-, 384- and 1536-welland is the first ... has been optimized to dispense from four ...
A univariate (peak height or area) quantitative multi-component analysis package....
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: